Literature DB >> 7526914

Monitoring canine lung allograft rejection using Ia antigen expression by bronchoalveolar lymphocytes.

S Akamine1, K Kawahara, T Takahashi, H Ayabe, M Tomita.   

Abstract

The expression of Ia antigens by lymphocytes in bronchoalveolar lavage (BAL) was evaluated after canine lung allotransplantation with immunosuppression using FK-506. The expression of Ia antigens labeled using an OKIa-1 monoclonal antibody from Ortho Diagnostic Systems was measured by flow cytometry. Twenty-three adult mongrel dogs underwent left lung allotransplantation and were treated with FK-506 at a dose of 0.1 mg/kg/day intramuscularly until death. Allograft rejection was evaluated microscopically. The percentage of OKIa-1-positive cells among the BAL lymphocytes was 34.8% +/- 8.9% (mean +/- SD) from the allografted lungs showing no rejection, whereas it was 68.8% +/- 16.2% from the allografted lungs which showed rejection (P < 0.01). When a diagnosis of rejection was made prior to pathologic examination by an OKIa-1-positive lymphocyte percentage of 42% or more, the sensitivity, specificity, and accuracy of diagnosis were 100%, 87.5%, and 94.1%, respectively. Subsequently, pulse steroid therapy was attempted in those dogs with a high rate of OKIa-1-positive lymphocytes in the BAL. In 3 of 4 dogs showing histological signs of rejection, a decrease in the rate of OKIa-1-positive cells among the BAL lymphocytes corresponded to an improvement in pathologic diagnosis. In two dogs with bacterial pneumonia and pulmonary vein thrombosis, densities indistinguishable from those of rejection were seen on chest roentgenograms, but in these dogs the rate of OKIa-1-positive BAL lymphocytes was 42% or less. In conclusion, Ia antigen expression by BAL lymphocytes could be useful for monitoring rejection in lung allotransplantation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7526914     DOI: 10.1007/bf01636775

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  15 in total

1.  LUNG HOMOTRANSPLANTATION IN MAN.

Authors:  J D HARDY; W R WEBB; M L DALTON; G R WALKER
Journal:  JAMA       Date:  1963-12-21       Impact factor: 56.272

2.  Transvenous lung biopsy: a new technique.

Authors:  M Hakim; P Stovin; T English; J Wallwork
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

3.  Lymphocyte activation in bronchoalveolar lavages from heart-lung transplant recipients.

Authors:  A Zeevi; H Rabinowich; I Paradis; S Gryzan; J H Dauber; R L Hardesty; B Kormos; B Griffith; R J Duquesnoy
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

Review 4.  The regulatory role of macrophages in antigenic stimulation. Part Two: symbiotic relationship between lymphocytes and macrophages.

Authors:  E R Unanue
Journal:  Adv Immunol       Date:  1981       Impact factor: 3.543

5.  Bronchial omentopexy in canine lung allotransplantation.

Authors:  P Dubois; L Choiniere; J D Cooper
Journal:  Ann Thorac Surg       Date:  1984-09       Impact factor: 4.330

6.  Significance of biochemical markers in early detection of canine lung allograft rejection.

Authors:  S C Chang; H K Hsu; R P Perng; G M Shiao; C Y Lin
Journal:  Transplantation       Date:  1991-03       Impact factor: 4.939

Review 7.  Bronchoalveolar lavage.

Authors:  H Y Reynolds
Journal:  Am Rev Respir Dis       Date:  1987-01

8.  Unilateral lung transplantation for pulmonary fibrosis.

Authors: 
Journal:  N Engl J Med       Date:  1986-05-01       Impact factor: 91.245

9.  Crossreactivity between human and canine Ia antigens using a mouse monoclonal antibody (CIA).

Authors:  Y Iwaki; P I Terasaki; T Kinukawa; T H Thai; T Root; R Billing
Journal:  Transplantation       Date:  1983-08       Impact factor: 4.939

10.  Alveolar lavage cytology in transplanted lungs. I. Staining methods and findings in dogs with autografts and allografts without immunosuppression.

Authors:  U Achterrath; S Blümcke; S K Koerner; T Yipintsoi; S S Siegelman; P Chandler; J W Hagstrom; M Torres; J E Cobbah; P Fujii; F J Veith
Journal:  J Thorac Cardiovasc Surg       Date:  1975-04       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.